ArticleDiscover oncology2025
Circulating soluble fibroblast activation protein (FAP) in patients with intra-thoracic cancer undergoing chest radiation.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCirculating soluble fibroblast activation protein (FAP) is implicated in myocardial infarction, stroke, fibrosis and various cancers. This study investigates changes in FAP concentrations in patients with intra-thoracic malignancies undergoing chest radiation therapy to assess its potential as a biomarker for radiation-induced organ injury.
methodsEighteen patients with intra-thoracic cancers (lung, esophagus and metastatic) received chest radiation therapy. Blood samples were taken before and after treatment, and FAP concentrations were measured using an ELISA assay. A control group of 53 healthy volunteers was included for comparison.
resultsBaseline FAP concentrations were significantly lower in cancer patients (median 91 ng/mL, 25th-75th percentiles 72-123 ng/mL) compared to healthy controls (median 118 ng/mL, 25th-75th percentiles 104-140 ng/mL, P = 0.0002). No significant difference in FAP concentrations was found between baseline and post-radiation samples (median 91 vs. 108 ng/mL, P = 0.19). FAP concentrations were not influenced by cancer type, radiation dose or chemotherapy and did not predict patient survival. Time between baseline and final blood sampling was 31 days median (range 9-46 days) and median follow-up period was 20 months (range 15-30 months).
conclusionOur findings indicate that FAP concentrations do not reflect radiation-induced inflammation or fibrosis in the early period after radiation therapy. The small patient cohort and short duration between radiation therapy and FAP measurement may have limited our ability to detect changes in FAP related to long-term radiation effects. Further research with larger cohorts and longer follow-up periods is needed to better understand the role of FAP in cancer and response to radiation injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.